Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-06

AUTHORS

Zhao Yan, Zhong-ling Zhu, Zheng-zi Qian, Ge Hu, Hua-qing Wang, Wan-hui Liu, Guang Cheng

ABSTRACT

AIM: To evaluate the single- and multiple-dose pharmacokinetics of vincristine sulfate liposomes (VSLI) in patients with advanced solid tumors. METHODS: In single-dose pharmacokinetic study, 16 patients were administered VSLI (1.5, 2.0, or 2.3 mg·m(-2)) through intravenous infusion. Another 6 patients receiving vincristine sulfate (VCR, 2.0 mg) were taken as the control. In multiple-dose pharmacokinetic study, 12 patients were administered VSLI (1.5 or 1.8 mg·m(-2)) through intravenous infusion weekly for 4 consecutive weeks. The plasma concentration of VSLI was determined using the liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. RESULTS: After intravenous infusion of the single dose of VSLI, the plasma concentrations were characterized by bi-exponential decline curves. No statistically significant differences were observed between the main pharmacokinetic parameters in the 3 dose groups. Compared with the patients receiving VCR, the patients treated with VSLI displayed an increase in the area under the plasma concentration vs time curve (AUC), and a decrease in plasma clearance rates. On the 4th cycle in the multiple-dose study, the plasma concentration of VCR in all subjects prior to the weekly administration was below the lower limit of quantification (LLOQ). The calculated pharmacokinetic parameters from the subjects in the multiple- and single-dose (1.5 mg·m(-2)) groups had no significant differences. Although the administration of liposomal VCR may significantly elevate the plasma concentration of VCR, VSLI-associated adverse events were similar to those associated with conventional VCR. CONCLUSION: VSLI exhibits a lower clearance and a higher AUC compared with conventional VCR. No accumulation was observed in patients exposed to VSLI for 4 consecutive weeks. VSLI was generally tolerated in the subjects. The phase II dose of VSLI may be recommended as 4 doses of 1.5 mg·m(-2) for treatment of patients with advanced solid tumors. More... »

PAGES

aps201244

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/aps.2012.44

DOI

http://dx.doi.org/10.1038/aps.2012.44

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1040299020

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22669119


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Phytogenic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chromatography, Liquid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liposomes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tandem Mass Spectrometry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vincristine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yan", 
        "givenName": "Zhao", 
        "id": "sg:person.01040506625.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040506625.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhu", 
        "givenName": "Zhong-ling", 
        "id": "sg:person.01106622025.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106622025.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Qian", 
        "givenName": "Zheng-zi", 
        "id": "sg:person.01155121161.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155121161.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hu", 
        "givenName": "Ge", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tianjin Medical University Cancer Institute and Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411918.4", 
          "name": [
            "Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Hua-qing", 
        "id": "sg:person.01372344523.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372344523.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "State Key Laboratory of Long-acting and Targeting Drug Delivery System, Yantai 264003, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Wan-hui", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "State Key Laboratory of Long-acting and Targeting Drug Delivery System, Yantai 264003, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cheng", 
        "givenName": "Guang", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1097/cmr.0b013e328311aaa1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002784455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cmr.0b013e328311aaa1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002784455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001813-199410000-00010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002907101"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001813-199410000-00010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002907101"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00686017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009486042", 
          "https://doi.org/10.1007/bf00686017"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00686017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009486042", 
          "https://doi.org/10.1007/bf00686017"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-005-0145-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012574747", 
          "https://doi.org/10.1007/s00280-005-0145-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-005-0145-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012574747", 
          "https://doi.org/10.1007/s00280-005-0145-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1600-0447.1968.tb01983.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014175106"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002800050846", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015527088", 
          "https://doi.org/10.1007/s002800050846"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0091270006288953", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019139655"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0091270010381499", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021039028"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1995.98", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023880067", 
          "https://doi.org/10.1038/bjc.1995.98"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1995.98", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023880067", 
          "https://doi.org/10.1038/bjc.1995.98"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.24632", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032328195"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.24632", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032328195"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1040-8428(98)00023-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032683860"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jconrel.2005.01.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035059256"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.24359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037962971"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.24359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037962971"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1995.430", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039993229", 
          "https://doi.org/10.1038/bjc.1995.430"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1995.430", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039993229", 
          "https://doi.org/10.1038/bjc.1995.430"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002800050750", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050995530", 
          "https://doi.org/10.1007/s002800050750"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.2.697", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074265672"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075244064", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082692478", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-06", 
    "datePublishedReg": "2012-06-01", 
    "description": "AIM: To evaluate the single- and multiple-dose pharmacokinetics of vincristine sulfate liposomes (VSLI) in patients with advanced solid tumors.\nMETHODS: In single-dose pharmacokinetic study, 16 patients were administered VSLI (1.5, 2.0, or 2.3 mg\u00b7m(-2)) through intravenous infusion. Another 6 patients receiving vincristine sulfate (VCR, 2.0 mg) were taken as the control. In multiple-dose pharmacokinetic study, 12 patients were administered VSLI (1.5 or 1.8 mg\u00b7m(-2)) through intravenous infusion weekly for 4 consecutive weeks. The plasma concentration of VSLI was determined using the liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.\nRESULTS: After intravenous infusion of the single dose of VSLI, the plasma concentrations were characterized by bi-exponential decline curves. No statistically significant differences were observed between the main pharmacokinetic parameters in the 3 dose groups. Compared with the patients receiving VCR, the patients treated with VSLI displayed an increase in the area under the plasma concentration vs time curve (AUC), and a decrease in plasma clearance rates. On the 4th cycle in the multiple-dose study, the plasma concentration of VCR in all subjects prior to the weekly administration was below the lower limit of quantification (LLOQ). The calculated pharmacokinetic parameters from the subjects in the multiple- and single-dose (1.5 mg\u00b7m(-2)) groups had no significant differences. Although the administration of liposomal VCR may significantly elevate the plasma concentration of VCR, VSLI-associated adverse events were similar to those associated with conventional VCR.\nCONCLUSION: VSLI exhibits a lower clearance and a higher AUC compared with conventional VCR. No accumulation was observed in patients exposed to VSLI for 4 consecutive weeks. VSLI was generally tolerated in the subjects. The phase II dose of VSLI may be recommended as 4 doses of 1.5 mg\u00b7m(-2) for treatment of patients with advanced solid tumors.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/aps.2012.44", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1023225", 
        "issn": [
          "1671-4083", 
          "1745-7254"
        ], 
        "name": "Acta Pharmacologica Sinica", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "33"
      }
    ], 
    "name": "Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors", 
    "pagination": "aps201244", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/aps.2012.44"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1040299020"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "bff7a7c1d19190ff3b805b6106c496e8d5ff7b2bf4286ef92749269c5eb9621e"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100956087"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22669119"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/aps.2012.44", 
      "https://app.dimensions.ai/details/publication/pub.1040299020"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-16T06:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000377_0000000377/records_106825_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://www.nature.com/articles/aps201244"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/aps.2012.44'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/aps.2012.44'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/aps.2012.44'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/aps.2012.44'


 

This table displays all metadata directly associated to this object as RDF triples.

238 TRIPLES      21 PREDICATES      64 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/aps.2012.44 schema:about N42910b3e55c7441783047092c3f7cde6
2 N42aa0af768054f7cb5da7ee5614326c3
3 N79140b7967254456968b72f92b165f5f
4 N7aaf0a0f67ab49819d34b627ebf18235
5 N9472788464cb45aeae4d61edea569d6f
6 N96bd32ada86246cab77ab79f5a56658c
7 N984066df96c1431cbfce1e5c778144b1
8 Nb13e8b6a050a46f0a799d2411ee5c1b2
9 Nb4922995887a4d548fa628cc6b0d6ccf
10 Nb6ce46daacf4450daa64cfc779c4fcd8
11 Nc64dee9760fb42e384df4c66f00655f3
12 Nc8a055c33a59462b9eab056d837a7703
13 Ncdcdd43811c7487db75c64af847e2c3d
14 Nd7c832d1cf58482fb230c3d97b8df0a1
15 Nd9e4596eb38a4bc5acf659c9f60c95c2
16 Nfbc2ad7370204a539c1a747298b38ca8
17 Nff94bc991024472b9bbcc000eb965538
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author N508e45ae97db4338af892709181f5415
21 schema:citation sg:pub.10.1007/bf00686017
22 sg:pub.10.1007/s00280-005-0145-x
23 sg:pub.10.1007/s002800050750
24 sg:pub.10.1007/s002800050846
25 sg:pub.10.1038/bjc.1995.430
26 sg:pub.10.1038/bjc.1995.98
27 https://app.dimensions.ai/details/publication/pub.1075244064
28 https://app.dimensions.ai/details/publication/pub.1082692478
29 https://doi.org/10.1002/cncr.24359
30 https://doi.org/10.1002/cncr.24632
31 https://doi.org/10.1016/j.jconrel.2005.01.010
32 https://doi.org/10.1016/s1040-8428(98)00023-7
33 https://doi.org/10.1097/00001813-199410000-00010
34 https://doi.org/10.1097/cmr.0b013e328311aaa1
35 https://doi.org/10.1111/j.1600-0447.1968.tb01983.x
36 https://doi.org/10.1177/0091270006288953
37 https://doi.org/10.1177/0091270010381499
38 https://doi.org/10.1200/jco.1999.17.2.697
39 schema:datePublished 2012-06
40 schema:datePublishedReg 2012-06-01
41 schema:description AIM: To evaluate the single- and multiple-dose pharmacokinetics of vincristine sulfate liposomes (VSLI) in patients with advanced solid tumors. METHODS: In single-dose pharmacokinetic study, 16 patients were administered VSLI (1.5, 2.0, or 2.3 mg·m(-2)) through intravenous infusion. Another 6 patients receiving vincristine sulfate (VCR, 2.0 mg) were taken as the control. In multiple-dose pharmacokinetic study, 12 patients were administered VSLI (1.5 or 1.8 mg·m(-2)) through intravenous infusion weekly for 4 consecutive weeks. The plasma concentration of VSLI was determined using the liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. RESULTS: After intravenous infusion of the single dose of VSLI, the plasma concentrations were characterized by bi-exponential decline curves. No statistically significant differences were observed between the main pharmacokinetic parameters in the 3 dose groups. Compared with the patients receiving VCR, the patients treated with VSLI displayed an increase in the area under the plasma concentration vs time curve (AUC), and a decrease in plasma clearance rates. On the 4th cycle in the multiple-dose study, the plasma concentration of VCR in all subjects prior to the weekly administration was below the lower limit of quantification (LLOQ). The calculated pharmacokinetic parameters from the subjects in the multiple- and single-dose (1.5 mg·m(-2)) groups had no significant differences. Although the administration of liposomal VCR may significantly elevate the plasma concentration of VCR, VSLI-associated adverse events were similar to those associated with conventional VCR. CONCLUSION: VSLI exhibits a lower clearance and a higher AUC compared with conventional VCR. No accumulation was observed in patients exposed to VSLI for 4 consecutive weeks. VSLI was generally tolerated in the subjects. The phase II dose of VSLI may be recommended as 4 doses of 1.5 mg·m(-2) for treatment of patients with advanced solid tumors.
42 schema:genre research_article
43 schema:inLanguage en
44 schema:isAccessibleForFree true
45 schema:isPartOf Nb5ca7153f99d4e09ae38540f94e76555
46 Nb6308c08c5ec4e1a85a92fea6af1e097
47 sg:journal.1023225
48 schema:name Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors
49 schema:pagination aps201244
50 schema:productId N3dbf083c600a4554affd4840709700a7
51 N482df8c7cb24430283f2c324453ab17c
52 N75cb0e5bbe264948aff6587a3fdff13b
53 N80e3e498db8444e5adda4abeeaf9a54f
54 Nb2829f2e9b314e41b2742682e50fb675
55 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040299020
56 https://doi.org/10.1038/aps.2012.44
57 schema:sdDatePublished 2019-04-16T06:23
58 schema:sdLicense https://scigraph.springernature.com/explorer/license/
59 schema:sdPublisher Neaa4af157d7d48b28b9d31f68148750c
60 schema:url http://www.nature.com/articles/aps201244
61 sgo:license sg:explorer/license/
62 sgo:sdDataset articles
63 rdf:type schema:ScholarlyArticle
64 N0804852802c74844a2076437cb8768e4 rdf:first Nf6da3fcc3099472ab6bb2878b5a934aa
65 rdf:rest N5965d8f6ba8247928fbdd53dd47bc5fc
66 N1d328d1c81ae4e45a6cdf59caeaed8b0 rdf:first sg:person.01372344523.47
67 rdf:rest N0804852802c74844a2076437cb8768e4
68 N2636ffa1326c48bf947adc3d2d662a32 rdf:first sg:person.01155121161.44
69 rdf:rest Nef377ec7745343adb0c4837bb67c6cd1
70 N3dbf083c600a4554affd4840709700a7 schema:name doi
71 schema:value 10.1038/aps.2012.44
72 rdf:type schema:PropertyValue
73 N42910b3e55c7441783047092c3f7cde6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Area Under Curve
75 rdf:type schema:DefinedTerm
76 N42aa0af768054f7cb5da7ee5614326c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Vincristine
78 rdf:type schema:DefinedTerm
79 N482df8c7cb24430283f2c324453ab17c schema:name dimensions_id
80 schema:value pub.1040299020
81 rdf:type schema:PropertyValue
82 N508e45ae97db4338af892709181f5415 rdf:first sg:person.01040506625.21
83 rdf:rest Nba91d983850b4d519ca6e95f53abea3f
84 N5965d8f6ba8247928fbdd53dd47bc5fc rdf:first N84b77cffa6824c238d1dbf7e8b46f85d
85 rdf:rest rdf:nil
86 N5d5251fbe56e4b21b37d5a8cd9e55d94 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
87 schema:familyName Hu
88 schema:givenName Ge
89 rdf:type schema:Person
90 N690a4dd74c4f4b0a9af67c47ff8afa59 schema:name State Key Laboratory of Long-acting and Targeting Drug Delivery System, Yantai 264003, China
91 rdf:type schema:Organization
92 N75cb0e5bbe264948aff6587a3fdff13b schema:name nlm_unique_id
93 schema:value 100956087
94 rdf:type schema:PropertyValue
95 N79140b7967254456968b72f92b165f5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Adolescent
97 rdf:type schema:DefinedTerm
98 N7aaf0a0f67ab49819d34b627ebf18235 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Middle Aged
100 rdf:type schema:DefinedTerm
101 N80e3e498db8444e5adda4abeeaf9a54f schema:name pubmed_id
102 schema:value 22669119
103 rdf:type schema:PropertyValue
104 N84b77cffa6824c238d1dbf7e8b46f85d schema:affiliation Nca845cb39a4a4b1e9c5e5003365dae87
105 schema:familyName Cheng
106 schema:givenName Guang
107 rdf:type schema:Person
108 N9472788464cb45aeae4d61edea569d6f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Drug Administration Schedule
110 rdf:type schema:DefinedTerm
111 N96bd32ada86246cab77ab79f5a56658c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Male
113 rdf:type schema:DefinedTerm
114 N984066df96c1431cbfce1e5c778144b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Chromatography, Liquid
116 rdf:type schema:DefinedTerm
117 Nb13e8b6a050a46f0a799d2411ee5c1b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Liposomes
119 rdf:type schema:DefinedTerm
120 Nb2829f2e9b314e41b2742682e50fb675 schema:name readcube_id
121 schema:value bff7a7c1d19190ff3b805b6106c496e8d5ff7b2bf4286ef92749269c5eb9621e
122 rdf:type schema:PropertyValue
123 Nb4922995887a4d548fa628cc6b0d6ccf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Young Adult
125 rdf:type schema:DefinedTerm
126 Nb5ca7153f99d4e09ae38540f94e76555 schema:volumeNumber 33
127 rdf:type schema:PublicationVolume
128 Nb6308c08c5ec4e1a85a92fea6af1e097 schema:issueNumber 6
129 rdf:type schema:PublicationIssue
130 Nb6ce46daacf4450daa64cfc779c4fcd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Tandem Mass Spectrometry
132 rdf:type schema:DefinedTerm
133 Nba91d983850b4d519ca6e95f53abea3f rdf:first sg:person.01106622025.65
134 rdf:rest N2636ffa1326c48bf947adc3d2d662a32
135 Nc64dee9760fb42e384df4c66f00655f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Aged
137 rdf:type schema:DefinedTerm
138 Nc8a055c33a59462b9eab056d837a7703 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Neoplasms
140 rdf:type schema:DefinedTerm
141 Nca845cb39a4a4b1e9c5e5003365dae87 schema:name State Key Laboratory of Long-acting and Targeting Drug Delivery System, Yantai 264003, China
142 rdf:type schema:Organization
143 Ncdcdd43811c7487db75c64af847e2c3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Female
145 rdf:type schema:DefinedTerm
146 Nd7c832d1cf58482fb230c3d97b8df0a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Antineoplastic Agents, Phytogenic
148 rdf:type schema:DefinedTerm
149 Nd9e4596eb38a4bc5acf659c9f60c95c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Humans
151 rdf:type schema:DefinedTerm
152 Neaa4af157d7d48b28b9d31f68148750c schema:name Springer Nature - SN SciGraph project
153 rdf:type schema:Organization
154 Nef377ec7745343adb0c4837bb67c6cd1 rdf:first N5d5251fbe56e4b21b37d5a8cd9e55d94
155 rdf:rest N1d328d1c81ae4e45a6cdf59caeaed8b0
156 Nf6da3fcc3099472ab6bb2878b5a934aa schema:affiliation N690a4dd74c4f4b0a9af67c47ff8afa59
157 schema:familyName Liu
158 schema:givenName Wan-hui
159 rdf:type schema:Person
160 Nfbc2ad7370204a539c1a747298b38ca8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Adult
162 rdf:type schema:DefinedTerm
163 Nff94bc991024472b9bbcc000eb965538 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Infusions, Intravenous
165 rdf:type schema:DefinedTerm
166 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
167 schema:name Medical and Health Sciences
168 rdf:type schema:DefinedTerm
169 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
170 schema:name Clinical Sciences
171 rdf:type schema:DefinedTerm
172 sg:journal.1023225 schema:issn 1671-4083
173 1745-7254
174 schema:name Acta Pharmacologica Sinica
175 rdf:type schema:Periodical
176 sg:person.01040506625.21 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
177 schema:familyName Yan
178 schema:givenName Zhao
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040506625.21
180 rdf:type schema:Person
181 sg:person.01106622025.65 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
182 schema:familyName Zhu
183 schema:givenName Zhong-ling
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106622025.65
185 rdf:type schema:Person
186 sg:person.01155121161.44 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
187 schema:familyName Qian
188 schema:givenName Zheng-zi
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155121161.44
190 rdf:type schema:Person
191 sg:person.01372344523.47 schema:affiliation https://www.grid.ac/institutes/grid.411918.4
192 schema:familyName Wang
193 schema:givenName Hua-qing
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372344523.47
195 rdf:type schema:Person
196 sg:pub.10.1007/bf00686017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009486042
197 https://doi.org/10.1007/bf00686017
198 rdf:type schema:CreativeWork
199 sg:pub.10.1007/s00280-005-0145-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1012574747
200 https://doi.org/10.1007/s00280-005-0145-x
201 rdf:type schema:CreativeWork
202 sg:pub.10.1007/s002800050750 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050995530
203 https://doi.org/10.1007/s002800050750
204 rdf:type schema:CreativeWork
205 sg:pub.10.1007/s002800050846 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015527088
206 https://doi.org/10.1007/s002800050846
207 rdf:type schema:CreativeWork
208 sg:pub.10.1038/bjc.1995.430 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039993229
209 https://doi.org/10.1038/bjc.1995.430
210 rdf:type schema:CreativeWork
211 sg:pub.10.1038/bjc.1995.98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023880067
212 https://doi.org/10.1038/bjc.1995.98
213 rdf:type schema:CreativeWork
214 https://app.dimensions.ai/details/publication/pub.1075244064 schema:CreativeWork
215 https://app.dimensions.ai/details/publication/pub.1082692478 schema:CreativeWork
216 https://doi.org/10.1002/cncr.24359 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037962971
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1002/cncr.24632 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032328195
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1016/j.jconrel.2005.01.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035059256
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1016/s1040-8428(98)00023-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032683860
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1097/00001813-199410000-00010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002907101
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1097/cmr.0b013e328311aaa1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002784455
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1111/j.1600-0447.1968.tb01983.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1014175106
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1177/0091270006288953 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019139655
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1177/0091270010381499 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021039028
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1200/jco.1999.17.2.697 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074265672
235 rdf:type schema:CreativeWork
236 https://www.grid.ac/institutes/grid.411918.4 schema:alternateName Tianjin Medical University Cancer Institute and Hospital
237 schema:name Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China
238 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...